Ticker
CELC
1 report from NewsMeter on CELC, newest first.
Celcuity (CELC) files sNDA for REVTORPYK in PIK3CA-mutant breast cancer, hazard ratio 0.50 from Phase 3
Regulatory
Aug 26, 2026
← All tickers